FY2017 EPS Estimates for Pfizer Inc. Reduced by Analyst (PFE)
Pfizer Inc. (NYSE:PFE) – Equities research analysts at Leerink Swann dropped their FY2017 EPS estimates for shares of Pfizer in a note issued to investors on Tuesday. Leerink Swann analyst S. Fernandez now forecasts that the brokerage will post earnings of $2.74 per share for the year, down from their previous estimate of $2.75. Leerink Swann also issued estimates for Pfizer’s FY2018 earnings at $2.90 EPS.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 EPS for the quarter, beating the consensus estimate of $0.62 by $0.02. The firm had revenue of $13.10 billion for the quarter, compared to analyst estimates of $13.01 billion. Pfizer had a return on equity of 23.37% and a net margin of 14.88%. The business’s revenue for the quarter was up 10.9% on a year-over-year basis. During the same quarter last year, the firm posted $0.56 earnings per share.
A number of other equities analysts have also weighed in on PFE. TheStreet raised Pfizer from a “hold” rating to a “strong-buy” rating in a research note on Friday, June 3rd. Vetr raised Pfizer from a “hold” rating to a “buy” rating and set a $36.89 price objective on the stock in a research note on Tuesday, June 7th. Jefferies Group reissued a “buy” rating and set a $42.00 price objective (up previously from $41.00) on shares of Pfizer in a research note on Tuesday, June 14th. Deutsche Bank AG reissued a “buy” rating on shares of Pfizer in a research note on Wednesday, June 15th. Finally, Piper Jaffray Cos. reissued an “overweight” rating and set a $54.00 price objective on shares of Pfizer in a research note on Monday, June 27th. Ten analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $38.78.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/fy2017-eps-estimates-for-pfizer-inc-reduced-by-analyst-pfe.html
Shares of Pfizer (NYSE:PFE) traded up 0.645% during trading on Wednesday, hitting $34.028. The stock had a trading volume of 8,861,345 shares. The stock has a market cap of $206.40 billion, a price-to-earnings ratio of 30.167 and a beta of 0.87. Pfizer has a 12 month low of $28.25 and a 12 month high of $37.39. The company’s 50 day moving average price is $34.80 and its 200 day moving average price is $33.87.
The company also recently announced a quarterly dividend, which was paid on Thursday, September 1st. Investors of record on Friday, August 5th were given a $0.30 dividend. The ex-dividend date of this dividend was Wednesday, August 3rd. This represents a $1.20 dividend on an annualized basis and a dividend yield of 3.55%. Pfizer’s dividend payout ratio (DPR) is presently 95.24%.
Several hedge funds have recently made changes to their positions in PFE. Nelson Roberts Investment Advisors LLC boosted its stake in shares of Pfizer by 6.7% in the second quarter. Nelson Roberts Investment Advisors LLC now owns 2,999 shares of the biopharmaceutical company’s stock worth $106,000 after buying an additional 189 shares during the period. Stelac Advisory Services LLC purchased a new stake in shares of Pfizer during the second quarter worth about $110,000. Tuttle Tactical Management LLC purchased a new stake in shares of Pfizer during the second quarter worth about $117,000. Catamount Wealth Management boosted its stake in shares of Pfizer by 14.2% in the first quarter. Catamount Wealth Management now owns 4,395 shares of the biopharmaceutical company’s stock worth $130,000 after buying an additional 545 shares during the period. Finally, Delphi Private Advisors LLC boosted its stake in shares of Pfizer by 1.2% in the second quarter. Delphi Private Advisors LLC now owns 4,007 shares of the biopharmaceutical company’s stock worth $141,000 after buying an additional 47 shares during the period. 69.65% of the stock is owned by hedge funds and other institutional investors.
Pfizer Company Profile
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.